MARKET WIREYahoo Finance • 21h ago
Lifecore Biomedical to Participate at Upcoming Industry ConferencesYahoo Finance report covering Lifecore Biomedical Inc. (LFCR) market action, institutional positioning, and fundamental catalysts.
Why LFCR Stock slipped -0.16% Today — RQD Quant Desk Flash
$6.39 -0.16% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $6.38
Lifecore Biomedical Inc. (LFCR) carries a Roarable Rating of C- (Hold) with 59/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
ROARABLE C- • HOLD / WATCH
Cap $242.3M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on LFCR Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is LFCR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Lifecore Biomedical Inc. (NASDAQ: LFCR) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 59/100 at a spot price of $6.39 (-0.16% 1D, market cap $242.3M). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 14/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, LFCR ranks #173 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does LFCR compare to IMRX and EVMN in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LFCR carries a Roarable C- (59/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, IMRX (Immuneering Corporation (Class A)) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $242.5M) and EVMN (Evommune Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $244.2M). Among the 5-stock peer group, LFCR leads on earnings multiple (N/A) while IMRX leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for LFCR?
▼
Per LFCR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001005286), Lifecore Biomedical Inc. generated $97.5M in revenue (-24.3% YoY), $0 in net income, and $0 in free cash flow against $232.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $6.38 (-0.22%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 11/20 (D+) • 7% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 59/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.2% avg 90D alpha vs SPY • 53.1% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERHOLD / WATCH • C-
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D+ · Rk C
Each axis scored 0–20
12M PRICE TARGET CONE+0.5% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LFCR)Realized 20D OHLCV Swing Band: ±1.9%
Deterministic 5-Pillar Attribution (59/100 Composite)
🔍 WHY LFCR SCORES 59/100 (C-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+14/20 pts (24% of score)
20D Institutional Volume Accumulation (±1.9% realized swing band)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (22% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)
Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade B-$6.42-0.8% Next Q
67
Q2 (-2Q)Grade C+$6.37+1.1% Next Q
64
Q3 (-1Q)Grade C+$6.44-0.8% Next Q
62
CurrentGrade C-$6.39+0.2% Hist 90D α
59
Trajectory: B- (67) → C- (59)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the LFCR Bull Thesis Could Fail
Even with a 59/100 (C-) score, LFCR faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Company executives have done more routine share selling than personal cash buying lately.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($5.50) or 200D SMA ($5.49) invalidates the momentum regime and cuts Target Base ($6.42) toward Bear Floor ($5.01).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $LFCR• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “LFCR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why LFCR Stock slipped -0.16% Today — RQD Quant Desk Flash
Lifecore Biomedical Inc. (LFCR) slipped -0.16% to $6.39, trading at 52% of its 52-week range ($3.63 – $8.98). Solid steady margins (steady margins), mixed timing at current multiples—hold if owned, no rush to chase.
- ▸Technical Tape: Trading at 52% of its 52-week range ($3.63 – $8.98) with RSI-14 at 61.7 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±1.9% around $6.39 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable C- (Hold) backed by 52% gross margin and $6.8M annual free cash flow.
Live LFCR Headlines & Catalysts
MARKET WIREBenzinga • 1d ago
Lifecore Biomedical Q2 2026 Earnings Call TranscriptBenzinga report covering Lifecore Biomedical Inc. (LFCR) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESupply Chain Digital • 1d ago
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RXO Inc. (NYSE – RXO), PTC Inc. (Nasdaq – PTC), Lifecore Biomedical, Inc. (Nasdaq – LFCR), WaFd, Inc. (Nasdaq – WAFD)Supply Chain Digital report covering Lifecore Biomedical Inc. (LFCR) market action, institutional positioning, and fundamental catalysts.
MARKET WIREMarketBeat • 1d ago
Lifecore Biomedical (LFCR) Short Interest & Short Float | Updated Oct 2026 $LFCRMarketBeat report covering Lifecore Biomedical Inc. (LFCR) market action, institutional positioning, and fundamental catalysts.
MARKET WIREWBOC TV • 1d ago
Are RXO, PTC, LFCR, WAFD Obtaining Fair Deals for their Shareholders?WBOC TV report covering Lifecore Biomedical Inc. (LFCR) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo! Finance Canada • 1d ago
Lifecore Biomedical, Inc. (LFCR) Seasonal Returns Chart - Yahoo FinanceYahoo! Finance Canada report covering Lifecore Biomedical Inc. (LFCR) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Traders Daily • 1d ago
The Technical Signals Behind (LFCR) That Institutions FollowStock Traders Daily report covering Lifecore Biomedical Inc. (LFCR) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 8d ago
Braemar Unveils Highly Qualified Independent Board Slate for Company’s New ChapterDALLAS, October 26, 2026--Braemar Hotels & Resorts Inc. (NYSE: BHR) ("Braemar" or the "Company") today announced that its Board of Directors (the "Board") intends to nominate eight highly qualified, seasoned leaders for
CATALYSTYahoo • 10d ago
Is Lifecore Biomedical (LFCR) an Asymmetric Risk-Reward in Pharma Contract Manufacturing?Diranko Capital, an independent investment management firm, released its Q3 2026 investor letter. The letter can be downloaded here. In the quarter, Diranko Capital achieved a 2.2% after-fee return, matching the MSCI ACW
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (LFCR Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
LFCR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +24.56%📐 HORIZONTAL RANGE
2026-11-03O $6.52H $6.52L $6.39C $6.39VOL 1.02M
RES: $7.34SUP: $3.89SMA50: $5.50SMA200: $5.49
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
LFCR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. -24.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on LFCR today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for LFCR. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for LFCR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LFCR)
Health Care Rank #173 of 1015
⚔️ IMRX vs LFCR Full Matrix →
1. Head-to-Head Health Care Peer Comparison (LFCR vs. IMRX, EVMN, IFRX, CAMP)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Lifecore Biomedical Inc. (LFCR) ranks #173 by composite RQD confidence (59/100, grade C-) and #548 by equity capitalization ($242.3M). Within this direct 5-issuer industry benchmark cohort, LFCR leads on earnings valuation at N/A trailing P/E, while IMRX leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. LFCR currently leads its immediate peer cohort in composite quantitative strength at 59/100 (C-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| LFCR
ACTIVE
Lifecore Biomedical Inc. | C- | 59/100 | — | — | — | -0.16% | $242.3M | Benchmark Subject |
| IMRX Immuneering Corporation (Class A) | E | 30/100 | — | — | -35.0% | -6.81% | $242.5M | /imrx-vs-lfcr → |
| EVMN Evommune Inc. | E | 31/100 | — | — | -35.0% | -10.70% | $244.2M | /evmn-vs-lfcr → |
| IFRX InflaRx N.V. | D+ | 54/100 | — | — | — | +6.33% | $244.6M | /ifrx-vs-lfcr → |
| CAMP CAMP4 Therapeutics Corporation | E | 26/100 | — | — | -35.0% | -4.67% | $248.5M | /camp-vs-lfcr → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001005286 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), Lifecore Biomedical Inc. (LFCR) reported GAAP revenue of $97.5M (-24.3% vs. FY2024 revenue of $128.9M , and +293.8% cumulative change since FY2023) , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, LFCR closed FY2025 with $232.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $97.5M | $0 | — | — | $232.2M | — |
| FY2024 (FY) | 2024-05-25 | $128.9M | -$38.7M | -$206.0K | -$13.6M | $255.4M | $110.5M |
| FY2023 (FY) | 2023-05-26 | $24.8M | $12.0M | $257.0K | $257.0K | — | — |
3. LFCR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs LFCR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Lifecore Biomedical Inc. (NASDAQ: LFCR) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 59/100 at a spot price of $6.39 (-0.16% 1D, market cap $242.3M). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 14/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, LFCR ranks #173 in composite RQD confidence.
How does LFCR compare to IMRX and EVMN in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LFCR carries a Roarable C- (59/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, IMRX (Immuneering Corporation (Class A)) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $242.5M) and EVMN (Evommune Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $244.2M). Among the 5-stock peer group, LFCR leads on earnings multiple (N/A) while IMRX leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for LFCR?
Per LFCR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001005286), Lifecore Biomedical Inc. generated $97.5M in revenue (-24.3% YoY), $0 in net income, and $0 in free cash flow against $232.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is LFCR trading relative to its 50-day, 200-day, and 52-week technical levels?
LFCR last traded at $6.39 (-0.16% on volume of 800,237 shares), positioning the stock +16.18% above its 50-day simple moving average ($5.50) and +16.39% above its 200-day simple moving average ($5.49). Across its 52-week range of $3.63 to $8.98, LFCR sits at the 51.6% percentile with a 14-day RSI of 61.7 (BULLISH MOMENTUM) and an implied next-earnings move of ±1.9% ($6.27 to $6.51).
ROARABLE RATING BRIEF • RQD 59/100 (C-)
✓ SEC XBRL & RQD VERIFIED
LFCR — Lifecore Biomedical Inc.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
Lifecore Biomedical Inc. (LFCR) earns a live Roarable RQD composite score of 59/100, corresponding to a C- letter grade (Roarable Hold) at a spot price of $6.39 (-0.16% 1D, market capitalization $242.3M).
- Fundamental Cash Engine (11/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
- Whale 13F & Options Flow (14/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (12/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
. (LFCR) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. — for product lines, customers, or revenue model specifics beyond the sector and industry classification.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Lifecore Biomedical Inc. (LFCR) reported $97.5M in annual revenue (up from $128.9M in FY2024, -24.3% YoY) and $0 in GAAP net income. Over the multi-year SEC filing window from FY2023 ($24.8M revenue, $12.0M net income) through FY2025, LFCR scaled operating cash flow to $0 and free cash flow to $0, backed by $232.2M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (C- • RQD 59/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 14/20. With Fundamental Cash Engine at 11/20 and Institutional Whale Flow at 14/20, sustained execution supports upside toward the upper end of the $3.63 – $8.98 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Upstream and downstream dependencies are — Sector correlation data is — Second-order bottlenecks cannot be identified from the supplied sources.
- Key Question #1: Can LFCR sustain or expand its — operating margin and — ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $97.5M and free cash flow of $0, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is LFCR's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
LFCR Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Lifecore Biomedical Inc. (LFCR) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance • 21h ago
Lifecore Biomedical to Participate at Upcoming Industry Conferences Yahoo Finance report covering Lifecore Biomedical Inc. (LFCR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Benzinga • 1d ago
Lifecore Biomedical Q2 2026 Earnings Call Transcript Benzinga report covering Lifecore Biomedical Inc. (LFCR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Supply Chain Digital • 1d ago
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RXO Inc. (NYSE – RXO), PTC Inc. (Nasdaq – PTC), Lifecore Biomedical, Inc. (Nasdaq – LFCR), WaFd, Inc. (Nasdaq – WAFD) Supply Chain Digital report covering Lifecore Biomedical Inc. (LFCR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE MarketBeat • 1d ago
Lifecore Biomedical (LFCR) Short Interest & Short Float | Updated Oct 2026 $LFCR MarketBeat report covering Lifecore Biomedical Inc. (LFCR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE WBOC TV • 1d ago
Are RXO, PTC, LFCR, WAFD Obtaining Fair Deals for their Shareholders? WBOC TV report covering Lifecore Biomedical Inc. (LFCR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago
Lifecore Biomedical, Inc. (LFCR) Seasonal Returns Chart - Yahoo Finance Yahoo! Finance Canada report covering Lifecore Biomedical Inc. (LFCR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Traders Daily • 1d ago
The Technical Signals Behind (LFCR) That Institutions Follow Stock Traders Daily report covering Lifecore Biomedical Inc. (LFCR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo • 8d ago
Braemar Unveils Highly Qualified Independent Board Slate for Company’s New Chapter DALLAS, October 26, 2026--Braemar Hotels & Resorts Inc. (NYSE: BHR) ("Braemar" or the "Company") today announced that its Board of Directors (the "Board") intends to nominate eight highly qualified, seasoned leaders for
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
LFCR Bull vs. Bear Conversation Board — What's Your Call at $6.39?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON LFCR 🐻 33% BEARISH CONVICTION
DE DeepValue_CFA RQD DEBATE OPENER • Institutional Buy-Side 🐂 BULLISH
🎯 Target: $8.26 (+29.1%)
📌 Pinned Debate The Forensic Balance Sheet pillar (13/20, Altman Z 2.5, Piotroski F 6/9, Debt/Equity 0.5) and the Whale 13F Flow pillar (13/20) indicat
The street is overcomplicating Lifecore Biomedical Inc. (LFCR). The Forensic Balance Sheet pillar (13/20, Altman Z 2.5, Piotroski F 6/9, Debt/Equity 0.5) and the Whale 13F Flow pillar (13/20) indicate financial survival metrics and some institutional interest are relatively stronger than the earnings base.. With an RQD score of 59/100 (C-) and Forensic Balance Sheet at 13/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $6.91.
SectorRotator 🐂 BULL
@SkepticalCFA Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.
SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH
🎯 Target: $5.18 (-19.1%)
Spot @ $6.40 The Fundamental Cash Engine pillar scores 11/20 with ROIC at 0% and FCF yield at 0%, and FY 2024 shows a net loss of -$38.7M on $128.9M
Careful chasing LFCR at $6.40. The Fundamental Cash Engine pillar scores 11/20 with ROIC at 0% and FCF yield at 0%, and FY 2024 shows a net loss of -$38.7M on $128.9M revenue.. Gross margin is 0.0%, but operating margin is 0.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $5.18 on multiple compression.